Regenerative medicine company Tengion (NASDAQ:TNGN) has always planned to take its novel tissue generating technology as far as early-stage clinical studies before finding a partner to finance later-stage work. The company’s lead program treating patients who have had their bladder removed is expected to finish phase 1 enrollment by year’s end. A preclinical kidney program […]
Regenerative medicine company Tengion (NASDAQ:TNGN) plans to start human studies on its experimental kidney disease treatment in 2013. Tengion said that it expects to file an investigational new drug application, or IND, with the U.S. Food and Drug Administration on its lead preclinical program in the first half of next year. Proof-of-concept data from the […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Regenerative medicine company Tengion (NASDAQ:TNGN) has relocated its headquarters from Pennsylvania to North Carolina, where the company maintains R&D operations. The move to North Carolina comes nearly two months after Tengion announced a corporate restructuring that included scaling back its Pennsylvania footprint and focusing its resources on the R&D facility in Winston-Salem, North Carolina. The […]
John L. Miclot has been appointed CEO of Tengion (NASDAQ:TNGN), a regenerative medicine business in East Norriton, Pennsylvania, as it pursues strategic partnership discussions. Miclot fills a vacancy left by Steven A. Nichtberger who resigned in June. David I Scheer, chairman of Tengion’s board, had taken a more active role in the company until a […]
Regenerative medicine company Tengion (NASDAQ:TNGN) is restructuring with moves that reduce headcount, focus operations on its North Carolina R&D arm and conserve enough cash to last another year. Tengion said the restructuring plan will allow the company to fund its lead development programs through key milestones next year while also cutting its spending. The company […]
Regenerative medicine is now Tim Bertram‘s work but in previous chapters of his career, he focused on drugs while working for large pharmaceutical companies such as Pfizer (NYSE:PFE), Smithkline Beecham Pharmaceuticals and Procter & Gamble (NYSE:PG). Bertram left big pharma seven years ago to join Tengion (NASDAQ:TNGN), whose tissue regeneration technology was originally developed at […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Regenerative medicine company Tengion‘s (NASDAQ:TNGN) Chief Scientific Officer Timothy Bertram will handle CEO duties while the company searches for a new top executive. Former CEO Dr. Steven Nichtberger resigned from the company on June 30. No reason was given for the resignation, but the company had said in securities filings that his departure “is not […]
Regenerative medicine company Tengion (NASDAQ:TNGN) has been granted orphan drug designation on its technology that is initially being developed to help patients with bladder cancer. Tengion’s platform technology for organ regeneration can create organs and tissues that the body will recognize as its own. The technology is intended to offer an alternative to current practices […]
Medtronic Inc. (NYSE:MDT) is hot on technology that could coax the body into producing its own replacement kidney. The Fridley, Minn.-based medical device maker revealed its 17 percent stake and a right of first refusal to purchase technology made by (NSDQ:Tengion Inc.) in regulatory filings April 13. The East Norriton, Pa.-based company is developing a […]